SIL204 demonstrated dose-dependent inhibition of up to 94% in pancreatic cancer cells harboring KRAS G12D mutations at nanomolar concentrations. SIL204 showed comparable efficacy of approximately 97% ...

) has been revised to $6.12 / share. This is a decrease of 33.33% from the prior estimate of $9.18 dated February 21, 2026. The price target is an average of many targets provided by analysts. The ...

Short interest in Silexion Therapeutics Corp (NASDAQ:SLXN) increased during the last reporting period, rising from 359.10K to 619.43K. This put 7.56% of the company's publicly available shares short.

Silexion Therapeutics Corp (NASDAQ:SLXN) has announced breakthrough preclinical results for its next-generation RNA interference (RNAi) therapy, SIL204, showing potent anti-tumor effects across three ...

Silexion Therapeutics (SLXN) stock saw a massive rally on Thursday following the release of new pre-clinical data from the clinical-stage biotechnology company. This pre-clinical trial was focused on ...

Detailed price information for Silexion Therapeutics Corp (SLXN-Q) from The Globe and Mail including charting and trades.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

View Silexion Therapeutics Corp SLXN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Silexion’s Revolutionary RNAi approach demonstrates powerful anti-tumor activity across three major KRAS-driven cancer types; Inhibition rate of ~90% observed in GP2D human colorectal cancer cells; ...